



February 6, 2013

ViperGen Enters New European School of DNA Nanotechnology to Enhance Research and Development

Copenhagen, Denmark, February 6, 2013 - - ViperGen ApS today announced that it has entered into a collaboration focused on DNA nanotechnology research and training.

A consortium between ViperGen ApS, baseclick GmbH (Germany), Microsoft Research Cambridge (UK), Aarhus University (Denmark), Ludwig Maximilian University of Munich (Germany), Technical University of Munich (Germany), Karolinska Institute (Sweden) and University of Oxford (UK) has been established with the objective of advancing DNA nanotechnology research and training. The project has been awarded approximately 4 million EUR from the European Commission 7th Framework Programme.

During the collaboration, ViperGen will focus on expanding the tool box of organic chemical reactions that are DNA-compatible and applicable to its YoctoReactor[®] drug discovery platform.

“We are delighted with the establishment of this collaboration. We believe that this consortium of leading European academic institutions and private companies within the field of DNA nanotechnology assembles the ideal combination of skills to accelerate advancement in this exciting field” said Nils Hansen, CEO of ViperGen ApS. “It is with great pleasure that we enter the new European School of DNA Nanotechnology to foster a new generation of scientists with the skill sets required to meet future challenges, and we are looking forward to a successful collaboration”.

About ViperGen ApS

ViperGen is dedicated to small molecule drug discovery using DNA-encoded chemical libraries.

ViperGen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.

ViperGen’s two 2nd generation technology platforms - The YoctoReactor[®] for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment[®] for screening of such libraries - are designed to deliver high fidelity drug discovery.

For further details about ViperGen and the YoctoReactor[®]/ Binder Trap Enrichment[®] drug discovery technology platforms please contact:

ViperGen ApS

Nils Hansen, CEO

Phone: +45 2523 6680

nha@viperGen.com